CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
近期接受 CAR-T 细胞治疗患者 FDG PET/CT 评估中并发的新发结核
英文原题：New Onset of Tuberculosis Complicating FDG PET/CT Evaluation in Patient With Recent Chimeric Antigen Receptor T-Cell Therapy.
查看英文原题
New Onset of Tuberculosis Complicating FDG PET/CT Evaluation in Patient With Recent Chimeric Antigen Receptor T-Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
一名16岁女孩因急性淋巴细胞白血病接受CD19 CAR-T 治疗后新发发热。CAR-T 后1个月及2个月进行的18F-FDG PET/CT显示纵隔淋巴结异常代谢灶，而治疗前未见。后续证实这些病灶是CAR-T 治疗后新发结核感染所致。
展开英文摘要原文
A 16-year-old adolescent girl with CD19 chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia experienced new onset of the fever. 18 F-FDG PET/CT studies acquired at 1 and 2 months, respectively, after CAR-T, showed foci of abnormal activity in the mediastinal lymph nodes not seen on the study before therapy.
However, these foci of abnormal activity were later proven due to newly developed tuberculosis after CAR T-cell therapy.
论文信息
- 作者
- Wang G、Yang X、Wang H、Wang W、Yang J
- 单位
- From the Department of Nuclear Medicine, Beijing Friendship Hospital of Capital Medical University.China
- 期刊
- Clinical nuclear medicine2023 Jul 1
- 原文标识
- PubMed 37083630 · DOI 10.1097/RLU.0000000000004655